Osteosarcoma

Revision as of 22:04, 21 November 2019 by Mtjordan91 (talk | contribs) (→‎See Also)

Background[1]

  • Most common primary pediatric bone tumor
    • 3% of all childhood cancers
  • Around two-thirds of those diagnosed with non-metastatic disease under the age of 40 will be long-term survivors or cured of the disease with appropriate treatment
  • Survival is less than 20 percent with metastatic disease
    • One-fifth will have metastases at presentation
    • Most common metastatic site is lung followed by bone
  • Bimodal as it peaks in early adolescence and over the age of 65

Pathophysiology

  • Overproduction of osteoid and immature bone by malignant osteoblasts

Clinical Features

  • Often an adolescent during a growth spurt
  • Bone pain for several months that worsens with activity and is more painful at night
  • Absence of constitutional symptoms (e.g., fevers, weight loss, night sweats, and decreased appetite are typically absent)
  • Large soft tissue mass on exam that is tender to palpation
  • Occurs at metaphysis of long bones
    • Most commonly at the distal femur followed by the proximal tibia
  • Less frequently presents as pathological fracture
  • Risk factors include prior cancer treatment, Paget disease of bone, benign bone disease, Hereditary Retinoblastoma or Li-Fraumeni syndrome

Differential Diagnosis

Malignant

Benign

Evaluation

  • X-ray
    • "Sunburst" pattern on X-ray
      • This pattern describes a lytic lesion with periosteal reaction and cortical disruption at or near the metaphysis
      • (A) Sunburst appearance of Osteosarcoma.
        (B) Ultrasound of same patient showing cortical destruction and boney mass.
    • Codman triangle
      • New subperiosteal bone formed when the periosteum is raised away from the bone
  • Elevated alkaline phosphatase
  • Elevated LDH
    • High LDH associated with poor outcome
  • Elevated ESR
  • MRI and biopsy for definitive diagnosis

Management

  • Pain control
  • Limb sparing surgery or amputation, if needed
    • Depends on location and extent of the primary tumor
  • Neoadjuvant chemotherapy
    • Response is a major prognostic factor
  • MAP therapy (methotrexate, doxorubicin, cisplatin) often regimen of choice for non-metastatic disease
    • No standard approach if metastatic
  • Typically, radiation resistant
    • If at base of skull or sacrum can consider intensity-modulated radiation therapy

Disposition

  • Home if patient can get expedited follow up
  • Admission and work-up if suspected delay in outpatient care

External Links

References

  1. Niederhuber, John E., et al. “Sarcomas.” Abeloff's Clinical Oncology E-Book. Elsevier Health Sciences, 2019, pp. 1604 – 1654.e8.